Maija Kiuru1, Danielle M Tartar2, Lihong Qi3, Danyang Chen3, Lan Yu2, Thomas Konia4, John D McPherson5, William J Murphy6, Maxwell A Fung4. 1. Department of Dermatology, University of California, Davis, Sacramento and Davis, California; Department of Pathology and Laboratory Medicine, University of California, Davis, Sacramento and Davis, California. Electronic address: mkiuru@ucdavis.edu. 2. Department of Dermatology, University of California, Davis, Sacramento and Davis, California. 3. Department of Public Health Sciences, University of California, Davis, Sacramento and Davis, California. 4. Department of Dermatology, University of California, Davis, Sacramento and Davis, California; Department of Pathology and Laboratory Medicine, University of California, Davis, Sacramento and Davis, California. 5. Department of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento and Davis, California. 6. Department of Dermatology, University of California, Davis, Sacramento and Davis, California; Department of Internal Medicine, University of California, Davis, Sacramento and Davis, California.
Abstract
BACKGROUND: A subset of melanomas carrying a B-Raf proto-oncogene, serine/threonine kinase gene (BRAF) V600E mutation, which is the most common targetable mutation in melanoma, arise in association with a melanocytic nevus that is also harboring a BRAF V600E mutation. The detailed histomorphologic characteristics of nevi positive for BRAF V600E have not been systematically documented. OBJECTIVE: To identify histomorphologic features correlating with BRAF V600E status in nevi. METHODS: We retrospectively identified melanocytic nevi from our laboratory reporting system. We performed a histomorphologic analysis and analysis of BRAF V600E expression by immunohistochemistry. RESULTS: Thirteen nevi (14.8%) were negative and 76 (86.4%) were positive for BRAF V600E. The nevi positive for BRAF V600E were predominantly dermal (predominantly dermal growth in 55.3% of nevi positive for BRAF V600E and 15.4% of nevi negative for BRAF V600E [P = .01]) and showed a congenital growth pattern (congenital growth pattern in 51.3% of nevi positive for BRAF V600E and 15.4% of nevi negative for BRAF V600E [P = .02]). Compared with nevi negative for BRAF V600E, those that were positive for BRAF V600E often exhibited predominantly nested intraepidermal melanocytes, larger junctional nests, abrupt lateral circumscription, and larger cell size. Architectural disorder and inflammatory infiltrates were seen more often in nevi negative for BRAF V600E. BRAF sequencing of a subset of nevi confirmed the immunohistochemical results. LIMITATIONS: Limitations include the study's retrospective design and the small sample size of nevi negative for BRAF V600E. CONCLUSIONS: BRAF V600E is associated with distinct histomorphologic features in nevi. These features may contribute to improving the accuracy of classification and diagnosis of melanocytic neoplasms.
BACKGROUND: A subset of melanomas carrying a B-Raf proto-oncogene, serine/threonine kinase gene (BRAF) V600E mutation, which is the most common targetable mutation in melanoma, arise in association with a melanocytic nevus that is also harboring a BRAF V600E mutation. The detailed histomorphologic characteristics of nevi positive for BRAF V600E have not been systematically documented. OBJECTIVE: To identify histomorphologic features correlating with BRAF V600E status in nevi. METHODS: We retrospectively identified melanocytic nevi from our laboratory reporting system. We performed a histomorphologic analysis and analysis of BRAF V600E expression by immunohistochemistry. RESULTS: Thirteen nevi (14.8%) were negative and 76 (86.4%) were positive for BRAF V600E. The nevi positive for BRAF V600E were predominantly dermal (predominantly dermal growth in 55.3% of nevi positive for BRAF V600E and 15.4% of nevi negative for BRAF V600E [P = .01]) and showed a congenital growth pattern (congenital growth pattern in 51.3% of nevi positive for BRAF V600E and 15.4% of nevi negative for BRAF V600E [P = .02]). Compared with nevi negative for BRAF V600E, those that were positive for BRAF V600E often exhibited predominantly nested intraepidermal melanocytes, larger junctional nests, abrupt lateral circumscription, and larger cell size. Architectural disorder and inflammatory infiltrates were seen more often in nevi negative for BRAF V600E. BRAF sequencing of a subset of nevi confirmed the immunohistochemical results. LIMITATIONS: Limitations include the study's retrospective design and the small sample size of nevi negative for BRAF V600E. CONCLUSIONS:BRAF V600E is associated with distinct histomorphologic features in nevi. These features may contribute to improving the accuracy of classification and diagnosis of melanocytic neoplasms.
Authors: John A Curtin; Jane Fridlyand; Toshiro Kageshita; Hetal N Patel; Klaus J Busam; Heinz Kutzner; Kwang-Hyun Cho; Setsuya Aiba; Eva-Bettina Bröcker; Philip E LeBoit; Dan Pinkel; Boris C Bastian Journal: N Engl J Med Date: 2005-11-17 Impact factor: 91.245
Authors: William M Lin; Su Luo; Alona Muzikansky; Alice Z C Lobo; Kenneth K Tanabe; Arthur J Sober; A Benedict Cosimi; Hensin Tsao; Lyn M Duncan Journal: J Am Acad Dermatol Date: 2014-10-18 Impact factor: 11.527
Authors: E Elizabeth Patton; Hans R Widlund; Jeffery L Kutok; Kamden R Kopani; James F Amatruda; Ryan D Murphey; Stephane Berghmans; Elizabeth A Mayhall; David Traver; Christopher D M Fletcher; Jon C Aster; Scott R Granter; A Thomas Look; Charles Lee; David E Fisher; Leonard I Zon Journal: Curr Biol Date: 2005-02-08 Impact factor: 10.834
Authors: Klaus P Hoeflich; Sylvia Herter; Janet Tien; Leo Wong; Leanne Berry; Jocelyn Chan; Carol O'Brien; Zora Modrusan; Somasekar Seshagiri; Mark Lackner; Howard Stern; Edna Choo; Lesley Murray; Lori S Friedman; Marcia Belvin Journal: Cancer Res Date: 2009-03-10 Impact factor: 12.701
Authors: Klaus J Busam; Cyrus Hedvat; Melissa Pulitzer; Andreas von Deimling; Achim A Jungbluth Journal: Am J Surg Pathol Date: 2013-03 Impact factor: 6.394
Authors: Pamela M Pollock; Ursula L Harper; Katherine S Hansen; Laura M Yudt; Mitchell Stark; Christiane M Robbins; Tracy Y Moses; Galen Hostetter; Urs Wagner; John Kakareka; Ghadi Salem; Tom Pohida; Peter Heenan; Paul Duray; Olli Kallioniemi; Nicholas K Hayward; Jeffrey M Trent; Paul S Meltzer Journal: Nat Genet Date: 2002-11-25 Impact factor: 38.330
Authors: A Hunter Shain; Iwei Yeh; Ivanka Kovalyshyn; Aravindhan Sriharan; Eric Talevich; Alexander Gagnon; Reinhard Dummer; Jeffrey North; Laura Pincus; Beth Ruben; William Rickaby; Corrado D'Arrigo; Alistair Robson; Boris C Bastian Journal: N Engl J Med Date: 2015-11-12 Impact factor: 91.245
Authors: David Dankort; David P Curley; Robert A Cartlidge; Betsy Nelson; Anthony N Karnezis; William E Damsky; Mingjian J You; Ronald A DePinho; Martin McMahon; Marcus Bosenberg Journal: Nat Genet Date: 2009-03-12 Impact factor: 38.330
Authors: Neil A Miller; Emily G Farrow; Margaret Gibson; Laurel K Willig; Greyson Twist; Byunggil Yoo; Tyler Marrs; Shane Corder; Lisa Krivohlavek; Adam Walter; Josh E Petrikin; Carol J Saunders; Isabelle Thiffault; Sarah E Soden; Laurie D Smith; Darrell L Dinwiddie; Suzanne Herd; Julie A Cakici; Severine Catreux; Mike Ruehle; Stephen F Kingsmore Journal: Genome Med Date: 2015-09-30 Impact factor: 11.117
Authors: Nadine H Brückmann; Sofie N Bennedsen; Pascal H G Duijf; Mikkel G Terp; Mads Thomassen; Martin Larsen; Christina B Pedersen; Torben Kruse; Nicolas Alcaraz; Henrik J Ditzel; Morten F Gjerstorff Journal: Cell Death Dis Date: 2019-11-06 Impact factor: 8.469
Authors: S Polubothu; N McGuire; L Al-Olabi; W Baird; N Bulstrode; J Chalker; D Josifova; D Lomas; J O'Hara; J Ong; D Rampling; P Stadnik; A Thomas; E Wedgeworth; N J Sebire; V A Kinsler Journal: Br J Dermatol Date: 2019-08-09 Impact factor: 9.302
Authors: Luz D Gutiérrez-Castañeda; Mauricio Gamboa; John A Nova; Leonardo Pulido; Jose D Tovar-Parra Journal: Biomed Res Int Date: 2020-07-22 Impact factor: 3.411